1 / 21

Volker Klauss, MD Patrick W. Serruys, Simon Wandel, Pawel Buszman,

LEADERS A Prospective, Randomised, Non-Inferiority Trial Comparing Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer. Volker Klauss, MD Patrick W. Serruys, Simon Wandel, Pawel Buszman,

georgettej
Download Presentation

Volker Klauss, MD Patrick W. Serruys, Simon Wandel, Pawel Buszman,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LEADERSA Prospective, Randomised, Non-Inferiority Trial Comparing Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer Volker Klauss, MDPatrick W. Serruys, Simon Wandel, Pawel Buszman, Axel Linke, Thomas Ischinger, Franz Eberli, Roberto Corti, William Wijns, Marie-Claude Morice, Carlo di Mario, Robert-Jan van Geuns, Pedro Eerdmans, Gerrit-Anne van Es, Peter Jüni, Stephan Windecker 2-Year Clinical Follow-Up

  2. Disclosures • Volker Klauss, MD • Nothing to disclose

  3. Background: LEADERS at 1-Year • Comparison of BES with biodegradable polymer to SES with durable polymer resulted in: • Non-inferior MACE rate at 9 months (primary endpoint met: 9.2% BES vs. 10.5% SES, Pnon-inf =0.003)* • Non-inferiority in MACE confirmed at 12 months (10.7% BES vs. 12.1% SES, Pnon-inf <0.001) • BES showed superior strut coverage and stent apposition at 9 months in OCT sub-analysis • Similar rates of stent thrombosis (ARC definition) at 12 months • Two year clinical outcomes have not yet been reported *Windecker S et al. THE LANCET 2008; 372 No 9644: 1163-1173

  4. Biolimus-A9™ Eluting Stent Biolimus is a semi-synthetic sirolimus analogue with 10x higher lipophilicity and similar potency as sirolimus. Biolimus is immersed at a concentration of 15.6 g/mm into a biodegradable polymer, polylactic acid, and applied solely to the abluminal stent surface by a fully automated process. Polylactic acid is co-released with biolimus and completely desolves into carbon dioxide and water after 6-9 months. The stainless steel stent platform has a strut thickness of 112 m with a quadrature link design.

  5. Trial Design Stable and ACS Patients Undergoing PCI Assessor-blind 1:1 Randomisation N=1700 Patients BES BioMatrix Flex N=850 SES Cypher Select N=850 1:3 Randomisation Clinical F/U N=640 Angio F/U N=210 Clinical F/U N=640 Angio F/U N=210 1o endpoint: CV death, MI, clinically-indicated TVR (9 month) 2o endpoints: Death, CV death, MI, TLR, TVR Stent thrombosis according to ARC Angiographic study: In-stent % diameter stenosis Late loss, binary restenosis DAPT recommended for 12 month

  6. Patient Eligibility • Inclusion Criteria • Coronary artery disease • - Stable angina • - Silent ischemia • Acute coronary syndrome • including UA, NSTEMI and STEMI • At least one lesion with • - Diameter stenosis > 50% • - RVD: 2.25-3.5 mm • - Number of lesions: no limitation • - Number of vessels: no limitation • Lesion length: no limitation • Written informed consent • Exclusion Criteria • Known allergy to • aspirin, clopidogrel, heparin, • stainless steel, sirolimus, biolimus, • contrast material • Planned, elective surgery within 6 months of PCI unless dual APT could be maintained • Pregnancy • Participation in another trial

  7. Patient Demographics BESSES857 Patients850 Patients Age in years 65  1165  11 Male gender 75%75% Arterial hypertension 74%73% Diabetes mellitus26%23% - insulin-dependent 10%9% Hypercholesterolemia 65%68% Family history 40%44% Smoking 24%25% Previous MI 32%33% Previous PCI36%37% - with drug-eluting stent 12%14% Previous CABG11%13% Chronic stable angina 45%44%

  8. Patient Characteristics BESSES 857 Patients850 Patients Acute coronary syndrome55%56% - Unstable angina 22%21% - Non-ST-elevation MI 17%18% - ST-elevation MI 16%17% Left ventricular ejection fraction56  11%55  12% Number of lesions per patient1.5  0.71.4  0.7 Lesions per patient - 1 lesion63% 69% - 2 lesions29% 22% - 3 lesions7% 8% - > 4 lesions1% 2% De novo lesions92% 91% Long lesions (>20 mm)31% 27% Small vessels (RVD <2.75 mm)68% 69% Off label use81% 78%

  9. Patient Flow - Clinical Randomized (N=1,707) BES (N=832) SES (N=823) SES (N=850) SES (N=829) BES (N=837) BES (N=857) 3 = Lost to F/U 6 = Patient withdrawal 12 = Other Lost to F/U = 2 Patient withdrawal = 9 Other = 9 1-year follow-up* (N=1,666; 97.6%) 2-year follow-up* (N=1,655; 97.0%) 0 = Lost to F/U 0 = Patient withdrawal 6 = Other Lost to F/U = 0 Patient withdrawal = 2 Other = 3 *F/U window ±28 days

  10. MACE 2-year HR 0.84 [0.65 to 1.08] P = 0.18* 15.4% Δ 2.4% 13.0% 1-year HR 0.88 [0.66 to 1.17] P = 0.37* 20 BES SES 15 12.1% Δ 1.4% % 10 10.7% 5 0 0 3 6 9 12 15 18 21 24 Months MACE = Cardiac Death, MI, or Clinically-Indicated TVR * P values for superiority

  11. Cardiac Death or MI 1-year HR 1.01 [0.70 to 1.45] P = 0.95* 2-year HR 0.92 [0.66 to 1.27] P = 0.59* 10 9.1% BES Δ0.8% SES 8 8.3% 6.9% Δ0% 6.9% 6 % 4 2 0 0 3 6 9 12 15 18 21 24 Months *P values for superiority

  12. Clinically-Indicated TVR 2-year HR 0.86 [0.62 to 1.20] P = 0.37* 1-year HR 0.82 [0.56 to 1.19] P = 0.29* 10 BES 8.8% SES Δ1.1% 8 7.2% 7.7% Δ1.2% 6 % 6.0% 4 2 0 0 3 6 9 12 15 18 21 24 Months *P values for superiority

  13. 2-Year Safety Endpoints P=0.71* P=0.42* P=0.57* P=0.35* P=0.24* P=0.59* % *P values for superiority

  14. 2-Year Efficacy Endpoints P=0.17* P=0.25* P=0.58* P=0.54* P=0.37* % 1 1 1Clinically Indicated *P values for superiority

  15. Stratified Analysis of MACE @ 2 Years .25 .5 1 2 4 P Value P Int Risk Ratio (95% CI) SES BES

  16. Definite ST through 2 years 3.0 2.5 2.0 1.5 1.0 0.5 0.0 0 3 6 9 12 15 18 21 24 Zoom at 1% scale 2.5% +0.5% BES SES 2.2% 2.0% +0.2% % 2.0%

  17. Primary and Secondary Definite ST BES N=857 SES* N=850 Definite Stent Thrombosis % According to ARC Definition *Includes one secondary, definite ST occurring at 60 days in a patient who had early ST at 3 days

  18. Antiplatelet Agent Utilization

  19. Effect of DAPT Discontinuation Overall Population Patient who d/c DAPT P = 0.73* % N=0/154 N=3/479 N=2/163 N=0/484 *P values for superiority

  20. Conclusions Overall population Non-inferiority of BES vs SES in an all-comers population was sustained up to 2 years In the overall LEADERS population there were similar outcomes for BES and SES with respect to: MACE - BES:13% vs SES: 15.4% (PSup= 0.18) Cardiac Death/MI - BES: 8.3% vs SES: 9.1% (PSup= 0.59) Clinically indicated TVR – BES:7.7% vs SES:8.8% (PSup=0.37)

  21. Conclusions Subgroup analysis STEMI patients improved rate of MACE with BES compared to SES (8.1% vs 19.3% Psup< 0.01) Very Late Stent Thrombosis Although this was an all-comers study, very late stent thrombosis events were rare (BES 0.2% vs SES 0.5% PSup= 0.73) There were no VLST events in BES patients following discontinuation of DAPT

More Related